February 04, 2020
1 min read

FDA: US metformin products safe from NDMA contamination

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

FDA-approved metformin products do not contain dangerous levels of nitrosodimethylamine, or NDMA, according to laboratory results released by the FDA.

As Healio previously reported, NDMA, which is a potentially carcinogenic agent, was found in metformin products in non-U.S. countries, causing the FDA to investigate metformin in the United States. Based on this investigation, the FDA found “not detectable to low levels” of NDMA in FDA-approved metformin, according to a press release.

In the release, the FDA advised the continued use of metformin for its indicated use for people with diabetes and stated that it will not be recalling U.S.-based metformin.

Enough NDMA evidence has previously been found in other medications to warrant recalls, including for the angiotensin receptor blocker valsartan as well as generic forms of Zantac (ranitidine). – by Phil Neuffer